These are the passionate and dedicated individuals that are the face, the heart, the brain, and the soul of the Sheila Singh Lab. They work tirelessly, inspired by the lives of patients. And, together, their efforts are expanding the frontiers of brain cancer research.
Sheila Singh, MD, PhD, FRCSC
Chitra Venugopal, PHD
Senior Research Associate
Responsible for planning, managing, and overseeing multiple research programs.
Mathieu Seyfrid, PHD
Post Doctoral Fellow
Elucidation of glioblastoma aggressiveness directly on cells and through their supportive environment, with chimeric antigen receptor (CAR) T-cells.
Blessing Bassey-Archibong, PHD
Post Doctoral Fellow
Identification of inherent molecular factors that drive brain metastasis.
Deepak Upreti, PHD
Post Doctoral Fellow
Development and generation of next generation CD133-based chimeric antigen receptor (CAR) T-cell for glioblastoma.
Fred Lam, MD, PHD, FRCSC
William Gwynne, PHD
Chirayu Chokshi, HBSc
Elucidation of synthetic and post-treatment vulnerabilities in glioblastoma through CRISPR-Cas9 based functional genomic platform.
Nazanin Tatari, Msc
Identification, validation and therapeutic targeting of novel tumor associated antigens for treatment-refractory glioblastoma.
Stefan Custers, MSc
Ashley Adile, HBSc
Identification of potent FDA-approved chemical compounds that specifically target recurrent medulloblastoma spinal metastases.
Neil Savage, HBSc
Investigation of novel stem cell markers for treatment of primary and recurrent glioblastoma.
Agata Kieliszek, HBSc
Identification of novel drug candidates that target and effectively inhibit brain metastases derived from lung, breast and melanoma primary tumours.
Sabra Salim, HBSc
Assessment and optimization of a CD133-specific chimeric antigen receptor (CAR) T-cell for glioblastoma.
Nikoo Aghaei, HBSc
Exploration the Wnt signalling pathway and its aberrant functioning in brain metastasis to develop targeted therapies for cancer patients.
William Maich, HBSc
Dillon McKenna, MSc
Animal research technician.
Undergraduate Researcher. Investigated new strategies to target brain metastases by 'retraining' the immune system to recognize and kill cancer cells.
Michelle Kameda-Smith, MD, PHD
Doctoral Candidate. Investigated the role of Musashi 1 in Group 3 medulloblastoma.
David Bakhshinyan, PHD
Doctoral Candidate. Characterized the molecular mechanisms underlying tumour recurrence in pediatric medulloblastoma by developing therapy adapted patient-derived xenograft models to uncover novel targeted therapies for patients who are largely limited to palliation.
Maleeha Qazi, PHD
Doctoral Candidate. Studied the treatment resistance and evolution of glioblastoma over the course of therapy with development of a pre-clinical, therapy-adapted model of tumour recurrence to identify personalized targets for therapeutic development.
Branavan Manoranjan, PHD
MD-Phd Candidate. Characterized intrinsic differences in the tumour-initiating capacity of Wnt and non-Wnt medulloblastomas with aims to discover whether Wnt activation in non-Wnt tumour could serve as a rationale for therapy for patients.
Nicolas Yelle, HBSc
Master’s Candidate. Studied the role of DKK1 as a novel candidate therapeutic target for recurrent glioblastoma.
Mohini Singh, PHD
Doctoral Candidate. Elucidated drivers of brain metastasis
Minomi K Subapanditha, HBSc
Parvez Vora, PHD
Post-Doctoral Fellow. Conducted preclinical validation studies of novel immunotherapies to target treatment-refractory glioblastoma cell population.
Dr. Sheila Singh | Pediatric Neurosurgeon, McMaster Children’s Hospital | Principal Investigator, McMaster Cancer Research Centre
Michael G. DeGroote Centre for Learning and Discovery, Room 5027 | McMaster University | 1280 Main Street West | Hamilton, Ontario L8S4K1
Dr. Sheila Singh | Pediatric Neurosurgeon, McMaster Children’s Hospital | Principal Investigator, McMaster Cancer Research Centre | Michael G. DeGroote Centre for Learning and Discovery, Room 5027 | McMaster University | 1280 Main Street West | Hamilton, Ontario L8S4K1